Evaluation of choice of medicine for hair growth in practising hair implant surgeons- original research

Siddarth Goudar; Santhi Priya Potharaju; Sharon Sylvia Dulapalli; Rahul VC Tiwari; Ashwin Hiremath; Damarasingu Rajesh

doi:10.53730/ijhs.v6nS7.11918

Authors

Siddarth Goudar Assistant Professor, Department of Oral and Maxillofacial Surgery, Gadag Institute of Medical Science, Gadag, Karnataka, India
Santhi Priya Potharaju Associate Professor, Department Of Periodontics, Government Dental College And Hospital, Afzalgung, Hyderabad, Telangana
Sharon Sylvia Dulapalli Assistant Professor, Department Of Periodontics, Government Dental College And Hospital, Afzalgung, Hyderabad, Telangana
Rahul VC Tiwari OMFS, FOGS, (MHA), PhD Scholar, Dept of OMFS, Narsinhbhai Patel Dental College and Hospital, Sankalchand Patel University, Visnagar, Gujarat, 384315
Ashwin Hiremath MDS, OMFS, FAM, Consultant Maxillofacial Surgeon at Redymed Health Care, Belgaum, Karnataka,India
Damarasingu Rajesh OMFS, PhD Scholar, Dept of OMFS, Narsinhbhai Patel Dental College and Hospital, Sankalchand Patel University, Visnagar, Gujarat

Keywords:

Androgenetic alopecia, hair regrowth, vitamins, minoxidil

Abstract

Aim The purpose of the present research was to assess the treatment effects of various pharmaceutical agents used by hair implant surgeons to induce hair growth in affected patients. Methodology this study, 500 patients we combined the use of antioxidants, iron, calcium, zinc, amino acids, and vitamins E, D, and C with minoxidil and finasteride to control hair loss, reverse miniaturization, and achieve new hair growth within 2-4 months with group I and II having male participants subjected to cyclic regimen and only minoxidil as well finasteride respectively whereas group II and IV had female participants also following cyclic as well as control regimen respectively. The patients were also followed clinically for 2 years and were observed to maintain their improvement. Results In Group I, the average improvement in density with cyclical medicine was 30% at 2 months and 52% at 4 months. The average improvement in caliber was 37% at 2 months and 47% at 4 months. In control Group II, density improved by an average of 2% at 2 months and 3.6% at 4 months. Caliber was unchanged in 44% of the patients.

Downloads

Download data is not yet available.

References

Paus R. Principles of hair cycle control. J Dermatol 1998;25:793–802.

Sperling LC, Mezebish DS. Hair diseases. Med Clin N Am 1998; 82:1155–69.

Price VH. Treatment of hair loss. N Engl J Med 1999;341:964–973.

Hamilton, J.B. Patterned loss of hair in man: Types and incidence. Ann. N. Y. Acad. Sci. 1951, 53, 708–728.

Paus, R.; Cotsarelis, G. The Biology of Hair Follicles. N. Engl. J. Med. 1999, 341, 491–497.

Rousso, D.E.; Kim, S.W. A Review of Medical and Surgical Treatment Options for Androgenetic Alopecia. JAMA Facial Plast. Surg. 2014, 16, 444.

Banka, N.; Bunagan, M.J.K.; Shapiro, J. Pattern Hair Loss in Men. Dermatol. Clin. 2013, 31, 129–140.

Yip, L.; Zaloumis, S.; Irwin, D.; Severi, G.; Hopper, J.; Giles, G.; Harrap, S.; Sinclair, R.; Ellis, J. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br. J. Dermatol. 2009, 161, 289–294.

Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical solution, placebo, and no treatment. J Am Acad Dermatol 1999;41(5 pt 1):717–21.

Sawaya ME, Shapiro J. Androgenetic alopecia. New approved and unapproved treatments. Dermatol Clin 2000;18:47–61.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Olsen EA, Funicella T, Koperski JA, Tschen-Cabrera EH. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2001;47:377–85.

Price VH, Menefee E. Quantitative estimation of hair growth. I. Androgenetic alopecia: effect of minoxidil. J Invest Dermatol 1990; 95:683–7.

Rundegren T, Trancik RJ. Stabilization of hair loss with minoxidil topical solution. Presented at the Third Intercontinental Meeting of Hair Research Societies, Tokyo, Japan, June 13–15, 2001.

Kassimir JJ. Use of topical minoxidil as a possible adjunct to hair transplant surgery. J Am Acad Dermatol 1987;16:685–7.

Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998;39:578–89.

Spencer, D.K. The Hormonal Effects of Diet on Hair Loss. In: The Bald Truth, Chapter 2. New York: Simon & Schuster Inc. 1998; 37-54.

Goodman & Gillman. The Pharmacological Basis of Therapeutics. 10th edition. 2005.

Diani, A.R., M.J. Mulholland, and K.L. Shull. Hair growth effects of oral administration of finasteride, a steroid 5-alpha reductase inhibitor, alone and in combination with topical minoxidil in the balding stump tail macaque. J Clin Endocrinol Metab. 1992; 74:345-350.